Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988817 · ClinicalTrials.gov registry record · Phase 1
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
A Phase 1 study, sponsored by Genmab.
- Completed
- Registry status
- Phase 1
- Development phase
- 306
- Enrollment target
NCT02988817: Completed Phase 1 study, sponsored by Genmab.
NCT02988817 is a Phase 1 study that has completed, run by Genmab. The registered enrollment target is 306 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (410% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02988817, a Phase 1 study, has completed, sponsored by Genmab.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 306 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
Primary Outcome
The DLTs were defined as Grade (G) 4 neutropenia or G4 thrombocytopenia for a minimal duration of 7 days, G3 and G4 febrile neutropenia, \>=G3 hemorrhage associated with \>=G3 thrombocytopenia, G4 anemia; Stevens Johnson syndrome, toxic epidermal necrolysis, \>=G3 cutaneous vasculitis; G3 neuropathy (not improved to G1 within 3 weeks following pausing of dosing) and G4 neuropathy; G3 infusion-related reactions (IRR) that did not resolve to G1 or baseline within 24 hours; G4 IRR or G4 anaphylaxis
Interventions
- BIOLOGICAL Enapotamab vedotin (HuMax-AXL-ADC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2016-11-23 |
| Est. Completion | 2021-11-12 |
| Phase | Phase 1 |
What the finished NCT02988817 record still lists
NCT02988817 is an interventional study that assigns participants to a tested intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (410% higher).
The record links to 0 conditions, and to 1 intervention - of which Enapotamab vedotin (HuMax-AXL-ADC) is the first listed.
NCT02988817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02988817 about?
NCT02988817 is a clinical study titled "Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors". The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
What is the current status of trial NCT02988817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 306 participants. The study started on 2016-11-23. Estimated completion is 2021-11-12.
What interventions are being tested in trial NCT02988817?
The interventions under investigation include: Enapotamab vedotin (HuMax-AXL-ADC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02988817?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02988817's enrollment target sits among peer trials
306 124th of 2000 higher than 1,877 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
- NCT06057337 · 306 participants · NA
Families With Pride ("Familias Con Orgullo").
- NCT06498635 · 306 participants · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI